| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967351 | Vaccine | 2012 | 6 Pages |
Abstract
⺠Recently, a recombinant human IgG1 monoclonal antibody (SII RMab) was developed to replace serum-derived immunoglobulin. ⺠A randomized dose-escalation phase 1 study along with rabies vaccine was conducted in healthy adults. ⺠SII RMab was well tolerated with similar reactions to the licensed human rabies immunoglobulin (HRIG). ⺠The antibody titers in the 10 IU/kg cohort were comparable to the vaccine plus HRIG cohort. ⺠Future post-exposure prophylaxis studies are planned.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Nithya Gogtay, Urmila Thatte, Nilima Kshirsagar, Brett Leav, Deborah Molrine, Peter Cheslock, Subhash V. Kapre, SII RMab author group SII RMab author group, Prasad S. Kulkarni,